Beilu Pharma(SZ:300016) Zhong Guo Jing Ji Wang·2025-09-29 08:33Core Viewpoint - Beilu Pharmaceutical plans to raise up to 300 million yuan through a simplified procedure for a private placement of shares, with the funds allocated for specific projects and working capital [1][2]. Group 1: Fundraising Details - The total amount to be raised is capped at 30,000,000 yuan, which will be used for the "Luzhibao Chemical Drug Production Workshop and Intelligent Comprehensive Warehouse Project," a 100-ton iodinated contrast agent production line upgrade, a 50-ton iodinated alcohol raw material drug production line upgrade, and to supplement working capital [1]. - The issuance will be limited to no more than 35 specific investors, including qualified institutional investors and other eligible entities as per the regulations of the China Securities Regulatory Commission (CSRC) [2]. - The pricing benchmark for the shares will be set at no less than 80% of the average trading price over the 20 trading days prior to the pricing date [2]. Group 2: Issuance Conditions - The number of shares to be issued will be determined by dividing the total fundraising amount by the issuance price, with a maximum limit of 30% of the company's total share capital prior to the issuance [3]. - Shares acquired through this issuance will be subject to a six-month lock-up period post-issuance [3]. - The issuance is contingent upon approval from the Shenzhen Stock Exchange and registration consent from the CSRC [1][3]. Group 3: Previous Financing Activities - In 2020, Beilu Pharmaceutical issued convertible bonds with a total face value of up to 500 million yuan, with a net fundraising amount of approximately 489.22 million yuan after deducting related expenses [4]. - The bonds were issued at a face value of 100 yuan each, totaling 5 million bonds, and the issuance was approved by the CSRC [4].